MIPLYFFA Drug Patent Profile

Which patents cover Miplyffa, and when can generic versions of Miplyffa launch?

Miplyffa is a drug marketed by Zevra Denmark and is included in one NDA. There are three patents protecting this drug.

This drug has forty-four patent family members in seventeen countries.

The generic ingredient in MIPLYFFA is arimoclomol citrate. One supplier is listed for this compound. Additional details are available on the arimoclomol citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Miplyffa

Miplyffa will be eligible for patent challenges on September 20, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 20, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for MIPLYFFA

International Patents:	44
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	16
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MIPLYFFA
What excipients (inactive ingredients) are in MIPLYFFA?	MIPLYFFA excipients list
DailyMed Link:	MIPLYFFA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MIPLYFFA

Constraining patent/regulatory exclusivity:

TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

NDA:

214927

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MIPLYFFA

Mechanism of Action

Organic Cation Transporter 2 Inhibitors

US Patents and Regulatory Information for MIPLYFFA

MIPLYFFA is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-001	Sep 20, 2024		RX	Yes	No
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-004	Sep 20, 2024		RX	Yes	Yes
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-002	Sep 20, 2024		RX	Yes	No
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-001	Sep 20, 2024		RX	Yes	No
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-003	Sep 20, 2024		RX	Yes	No
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-004	Sep 20, 2024		RX	Yes	Yes
Zevra Denmark	MIPLYFFA	arimoclomol citrate	CAPSULE;ORAL	214927-002	Sep 20, 2024		RX	Yes	No

International Patents for MIPLYFFA

See the table below for patents covering MIPLYFFA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E552010
Australia	2009262670
Brazil	122019024895
Brazil	PI0914684
Canada	2728363
Canada	3004867
China	102123729

Last updated: June 22, 2026

MIPLYFFA market dynamics and financial trajectory hinge on two inputs: (1) whether the product is launched and billed under a specific FDA approval and NDC with stable payer access, and (2) the pace of competitive substitution from authorized generics or alternative branded therapies. No market, financial, FDA regulatory, or patent-exclusivity data specific to “MIPLYFFA” is available in the provided context, and a complete, accurate market-and-finance analysis cannot be produced without that anchored product identity.

H1: MIPLYFFA market dynamics, sales trajectory, and competitive landscape

Is MIPLYFFA FDA-approved, and what’s the regulatory pathway that drives uptake?

Featured snippet answer: Cannot be determined from the provided information.

Approval status and labeling scope that typically govern early demand

MIPLYFFA uptake is usually determined by:

• Indication(s) and line of therapy
• Contraindications and required monitoring
• Dosing convenience and administration setting
• REMS requirements, if any
• Availability of companion diagnostics, if any
• Formulation format (oral vs injectable vs infusion) and associated payer friction

FDA pathway effects on speed to market and payer behavior

• Accelerated approval or breakthrough designations often correlate with earlier market entry but not necessarily with durable revenue.
• Standard approval can slow entry but tends to stabilize payer contracting if evidence is robust and endpoints align with reimbursement triggers.

What patents protect MIPLYFFA, and when does exclusivity end?

Featured snippet answer: Cannot be determined from the provided information.

Orange Book status and exclusivity timelines

A valid market forecast depends on:

• Whether the active ingredient has Orange Book listed patents
• Patent expiration dates by claim type (composition, formulation, method of use)
• Non-patent exclusivity (NCE/505(b)(2)/Orphan exclusivity), if applicable
• Expected generic or biosimilar entry windows, including paragraph IV strategy

Method-of-use and formulation claims that can extend commercial protection

Even after primary composition patent expiry, market access can remain blocked if:

• Dosing regimen patents restrict label-replicating generics
• Formulation patents block therapeutically equivalent substitution
• Patient-selection or monitoring method patents limit carve-outs

What generic or biosimilar entry risks exist for MIPLYFFA?

Featured snippet answer: Cannot be determined from the provided information.

Paragraph IV litigation typically drives revenue step-down timing

Revenue exposure usually accelerates when:

• A paragraph IV filing is accepted
• Infringement litigation reaches trial or settlement
• FDA approves a competing product ahead of litigation resolution

How settlement agreements shape launch dates

Settlement outcomes generally determine:

• “Launch-at-risk” timing versus delayed entry
• Carve-outs for specific strengths, routes, or indications
• Profit-sharing or license payments that may cap competitor revenue

How do payer dynamics and reimbursement shape MIPLYFFA net sales?

Featured snippet answer: Cannot be determined from the provided information.

Contracting and pricing mechanics that typically impact net-to-gross

For branded pharmaceuticals, net sales usually diverge from gross list price due to:

• Rebates and discounts tied to formulary tier placement
• Patient assistance programs
• Managed entry agreements and volume commitments
• ASP dynamics for payers moving between hospital and retail channels

Channel mix that often predicts volatility

Net sales trajectories usually correlate with:

• Mix of commercial vs government reimbursement
• Specialty pharmacy distribution vs buy-and-bill
• Site-of-care trends (hospital outpatient vs physician office)

What is the competitive set for MIPLYFFA, and how does it compare on value?

Featured snippet answer: Cannot be determined from the provided information.

Competitive positioning dimensions

Market dynamics typically turn on:

• Clinical differentiation versus standard of care
• Safety and monitoring burden
• Convenience (frequency, administration time)
• Evidence strength by subgroup
• Health economic value (cost per response, durability, avoided events)

Head-to-head and real-world utilization effects

• If head-to-head data favors MIPLYFFA, payer access tends to improve faster.
• If real-world adoption lags, net price pressure rises and switching accelerates.

What does the financial trajectory look like for MIPLYFFA over time?

Featured snippet answer: Cannot be determined from the provided information.

Sales curve drivers that define typical early- to mid-life revenue

Even without product-specific numbers, a credible trajectory requires anchoring:

• Initial launch month and subsequent quarterly billing ramp
• Reimbursement stability and formulary adoption cadence
• Competitor substitution speed post-launch
• Margin pressure from rebates and contracting

What commonly causes inflection points

• New indication approvals that expand addressable patient pool
• Safety communications or label restrictions that reduce uptake
• Supply constraints that delay shipments and postpone net sales
• Patent litigation outcomes that open or close substitution windows

What litigation and FDA enforcement events affect MIPLYFFA commercialization?

Featured snippet answer: Cannot be determined from the provided information.

Why regulatory actions matter for revenue

FDA label changes, REMS updates, manufacturing hold situations, or post-market safety signals can:

• Reduce prescriber confidence
• Trigger payer utilization management
• Cause temporary inventory and channel stocking shifts

Why IP litigation matters for revenue pacing

Patent outcomes can:

• Delay generic entry and sustain pricing
• Trigger earlier-than-expected price competition
• Alter contract strategy as payers anticipate substitutes

Commercial forecast: what are the scenarios for MIPLYFFA net revenue under different substitution paths?

Featured snippet answer: Cannot be determined from the provided information.

Scenario structure used in high-stakes revenue modeling

A practical forecast typically runs:

• Base case: slower-than-expected switching, stable contracting, no major label restriction
• Competition case: earlier generic entry, higher rebate rates, steeper net price decline
• Expansion case: additional indications or superior subpopulation fit increases share
• Disruption case: safety, supply, or payer reimbursement deterioration causes demand compression

Without the product’s FDA status, active ingredient, indication, and patent/IP schedule, these scenarios cannot be made concrete.

Key competitor-and-timing map for MIPLYFFA revenue exposure

Featured snippet answer: Cannot be determined from the provided information.

What must be present to build a competitor timing map

A usable map requires:

• Exact FDA product name and active ingredient
• Orange Book listed patents with expiry dates
• Documented paragraph IV and litigation docket history
• NDC launch timing and distribution channel start date
• Payer adoption benchmarks and share-of-voice metrics

Key Takeaways

• A complete market-dynamics and financial trajectory analysis for MIPLYFFA cannot be produced from the provided information.
• Revenue trajectory for any branded drug depends on anchored FDA approval identity, patent exclusivity schedule, payer contracting conditions, and competitive entry timing; none are available here for MIPLYFFA.

FAQs

1. What are the Orange Book listed patents for MIPLYFFA and their expiration dates?
2. Has MIPLYFFA faced any paragraph IV challenges or generic settlements, and what launch dates do they imply?
3. What payer reimbursement channels (commercial, Medicare, Medicaid, hospital buy-and-bill vs specialty pharmacy) drive MIPLYFFA net sales?
4. What does MIPLYFFA’s competitive set look like by mechanism, administration, and clinical differentiation?
5. What FDA label or safety events have affected MIPLYFFA prescribing patterns and utilization management?

References

1. APA style citation list would be generated from the cited FDA/Orange Book/patent/litigation and financial-source documents, but no sourceable materials are provided in the prompt.

DrugChatter Q&A for MIPLYFFA

Drug trials snapshot miplyffa fda?
Miplyffa arimoclomol fda label 214927?
Miplyffa ischemic stroke drug?
Miplyffa arimoclomol fda approval september 20 2024 label?
Zvra miplyffa patent orange book 2026?